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Abstract 
Hormone responsive breast cancer (BC) is the most common BC and relies on steroid 
hormones for cell proliferation and survival, therefore endocrine therapy; Tamoxifen (TAM), 
serves as the main therapeutic strategy in treating hormone receptor positive BC. Despite the 
use of TAM for over four decades, overcoming drug resistance remains challenging. Due to 
the fact that steroid hormones are derived from cholesterol and evidently, increased level of 
cholesterol is associated with cancer progression, in this research, we investigated the effect 
of reducing intracellular cholesterol as a possible alternative method to induce cell death in 
BC cells. An important protein involved in cholesterol homeostasis is the Cholesteryl Ester 
Transfer Protein (CETP). CETP maintains cholesterol homeostasis by storing cholesteryl 
esters (CEs) in lipid droplets. The intracellular accumulation of CEs leads to aggressive 
cancer development and drug resistance. Therefore, we aim to investigate whether CETP can 
possibly be used as a drug-resistance marker in BC. This study has shown that knocking-
down CETP resulted in increase in apoptosis in MCF-7 cells when treated with TAM (by 10-
40%) and various other drugs. Furthermore, CETP knock-down with the addition of a 
cholesterol-depleting agent increased apoptosis by 10 fold when compared to the non-
transfected MCF-7 cells, possibly due to a decrease in CE content. Similar results were 
observed in MDA-MB-231 cells. Therefore, it was concluded that CETP could thus serve as 
a potential drug-resistance marker in cancer cells, more specifically BC. Furthermore, 
strategies targeting CETP could be used as a potential combination treatment for treating 
cancer. 
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1. Introduction  
 
1.1 Prevalence of Cancer and BC 
Worldwide, cancer is the second leading cause of death with an estimated increase of 14 
million new cases reported yearly (WHO, 2018). In 2015, 8.8 million deaths were caused by 
cancer of which 521 000 deaths were caused by BC specifically (WHO, 2018). Shockingly, 
nearly 70% of BC cases and BC-related deaths occur in developing countries (WHO, 2018). 
In South Africa, a total of 3206 deaths were documented in the year 2000, and in 2012 the 
cancer registry estimated that one in every eight South African women are at risk of 
developing BC, thus ranking BC the leading cause of cancer deaths amongst other common 
cancers (Cansa, 2013). In addition, 8132 BC deaths were reported in 2013 making up a total 
of 22.22% of all cancer-related deaths (Cansa, 2013). 
 
1.2 Hallmarks of Cancer and BC 
Cancer is a well-known challenging disease that involves the abnormal or unrestricted cell 
proliferation that progress into neoplasms (Cansa, 2013). The various infamous hallmarks 
that define cancer include: over-proliferation, metastasis or invasion, and circumvention of 
apoptosis (Hanahan and Weinberg, 2011). BC is amongst the top five lethal cancers (cervical, 
colorectal, uterine and lung cancer) in South African women (Cansa, 2013). BC is a 
malignant tumour that develops in or around the various ducts and tissues in the breast 
(American Cancer Society, 2016). The metastatic nature and resistance to apoptosis makes 
BC one of the most difficult diseases to treat (Mazars et al., 1992). Apoptosis is a well-
established process of programmed cell death that leads to physiological and morphological 
changes in cells (Fig. 1.1) (Hanahan and Weinberg, 2011). There are two apoptotic pathways 
namely; intrinsic and extrinsic pathways. These pathways activate different cysteine-aspartic 
proteases (caspases) through various tumour suppressor proteins and genes to eliminate 
mutated cells (Putcha et al., 2002). In cancer, BC included, these pathways are suppressed 
thus leading to unhindered cell proliferation. Additionally, various proliferative pathways in 
BC; such as PI3K (phosphatidylinositol 3 kinase) or Akt (protein kinase B) pathway 
(Paplomata and O’Regan, 2014), Wnt and sonic hedgehog signalling pathway (Luchetti et al., 
2016; Sheng et al., 2014) and MAPK (mitogen-activated protein kinase) pathway (Derynck 
and Zhang, 2003; Moustakas and Heldin, 2005), are up-regulated through the interaction 
between steroid hormones and its respective cell surface receptors making BC an aggressive 
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cancer type. Therefore, emphasising the importance of advancing BC therapies (American 
Cancer Society, 2016).  
 
 
 
 
 
 
 
Apoptosis may occur through various internal and external stimuli (such as gene mutations 
or drugs respectively). During early apoptosis, cells undergo a membrane flip and begin to 
shrink. Thereafter, membrane blebbing occurs in apoptotic cells and starts to collapse and 
forms apoptotic bodies, which are digested by macrophages. (Figure adopted from: 
(Larrubia et al., 2013) . 
 
1.3 Hormone Induced BC 
Steroid hormones such as estrogen and progesterone synthesised from cholesterol serves as 
significant regulators of cell proliferation and differentiation in both normal cells as well as 
cancer cells (Ghayee and Auchus, 2007). 
In normal breast cells, steroid hormones maintain normal physiological and behavioural 
responses of breast cells such as reproduction and development (Anderson and Clarke, 2004). 
BC cells, however, can be identified or recognised based on the presence of surface receptors 
that are responsible for the binding of steroid hormones for cell proliferation (Wang et al., 
2015), and thus serve as a useful biomarker to define various cancer types. BC cells can, 
therefore, be estrogen or progesterone receptor positive (ER+, PR+), estrogen receptor 
negative (ER-), and triple negative. ER- BC cells are independent of steroid hormones and as 
a result, they are dependent on alternate means such as human epidermal growth factor (EGF) 
receptor (HER2) for cell proliferation (Cleator et al., 2007). Triple negative BC cells, 
Figure 1.1: Morphological changes to cells during apoptosis 
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however, lack both the hormone receptors (ER and PR)and HER2 (Cleator et al., 2007) but 
rather responds to insulin-like growth factors (IGF) for proliferation and cell survival 
(Davison et al., 2011). Despite the various BC types, ER+ BC still accounts for the majority 
(75%) of BC cases (Fig. 1.2) where these hormone-induced BC cells are reliant on hormones 
for promoting proliferative signals involved in cell proliferation, differentiation, migration 
and survival (Breastcancer.org, 2016).  For this reason, increased expressions of hormone 
receptors and elevated levels of estrogen are frequently associated with breast neoplasia. 
Therefore, it can be said that there is a positive correlation between estrogen levels or 
synthesis and the presence of hormone receptors. Furthermore, surface receptors are thus 
often used as a clinical biomarker to predict effectiveness of potential therapeutic strategies 
(Cianfrocca and Goldstein, 2004). 
 
 
Figure 1.2: Representative of prevalence of hormone induced BC types with the 
respective currently available drugs 
Receptor positive BC is the most common BC, accounting for about 75% of hormone induced 
BC. Currently, endocrine therapy is the most effective strategy in treating ER+ BC. In rare 
cases where BC cells are independent of hormones for cell growth and proliferation, 
treatment options become limited. These include: drugs targeting HER2 for hormone 
negative BC and chemotherapy and surgery for triple negative BC cells.  
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1.4 Available treatment for BC  
Limitations in BC therapies have been a burden for women world-wide hence the increasing 
death rate statistics. Chemotherapy is often used simultaneously with BC medications to treat 
both early stage and late stage BC (Breastcancer.org, 2016). Hormone therapy or endocrine 
therapy is the most widely used strategy that involves the use of selective ER modulators 
(SERMs), such as TAM, which has been the first-line or gold standard treatment for hormone 
responsive BC for over four decades (Maughan et al., 2010). TAM has anti-estrogen 
properties, playing an antagonistic role to the hormone estrogen (Hodges et al., 2003; Mourits 
et al., 2001). The National Surgical Adjuvant Breast and Bowel Project proposed that using 
TAM reduces or slows down 45% ER+ BC recurrences (Mourits et al., 2001). TAM is 
initially metabolised by a family of cytochrome P450 enzymes (Cronin-Fenton et al., 2014) 
into various active metabolites namely: endoxifen and 4-hydroxy-tamoxifen, both which 
competitively bind to the ERs of BC cells (Lu et al., 2012). The principle metabolite, 
endoxifen, was found to be produced from N-desmethyl-tamoxifen by an enzyme known as 
CYP2D6 (Lu et al., 2012), The metabolite is then internalised and binds to estrogen-
dependent genes thus reducing gene expression possibly through the recruitment of 
corepressors (Hodges et al., 2003). Consequently, this prevents the activity of various 
transcription factors thus impeding growth promoting signals for cellular replication (Hodges 
et al., 2003). Interestingly, TAM has also been found to have agonist properties, in which it 
promotes transcription by initiating the activator protein (AP-1) pathway in the uterine 
endometrium, bone and cardiovascular system (Hodges et al., 2003; Webb et al., 1995). 
However, long-term use of TAM has been reported to cause adverse side effects such as: 
early onset of menopausal symptoms, blood clots, endometrial cancer (Acconcia et al., 2006) 
and relapse (Breastcancer.org, 2016; Mourits et al., 2001). In addition, the continual use of 
TAM leads to a build-up of resistance against TAM and ultimately become ineffective in 
preventing BC and other cancers (Ring and Dowsett, 2004). It was found that at least 40% of 
patients eventually relapse after ±5 years of using TAM despite its therapeutic activities 
(Ring and Dowsett, 2004). Other popular drugs used to treat ER+ BC patients include the 
aromatase inhibitors. Aromatase inhibitors blocks the aromatase enzymes involved in the 
production of estrogen and thereby reducing the proliferation of ER+ cells (Breastcancer.org, 
2016). Another chemotherapeutic drug is 5-Fluorouracil (5-FU). 5-FU has been a widely 
studied chemotherapeutic drug as it is closely related to uracil, which is preferentially used by 
tumour cells for proliferation (Cohen et al., 1958). 5-FUis thus incorporated into RNA by 
replacing the uracil (Cohen et al., 1958). In addition, it also inhibits DNA synthesis by 
disrupting thymine production (Cohen et al., 1958). However, despite the use of these drugs, 
18 
 
drug resistance still remains a significant problem with regards to clinical use. Therefore, 
further research is needed to improve the response and decrease resistance to currently 
available dugs and therapeutic strategies. 
 
1.5 BC and link to cholesterol  
Steroid hormones are produced by the endocrine glands; adrenal cortex, testes, ovaries and 
peripheral tissues, such as the adipose tissues and the brain (Ghayee and Auchus, 2007). 
Hormone production is a highly complex process that involves a number of different 
pathways and enzymes (Fig. 1.3).  
 
Figure 1.3: The biosynthesis of cholesterol and the production of steroid hormones from 
cholesterol 
The biosynthesis of cholesterol initiates from acetyl-CoA (acetyl-coenzyme A), a by-product 
from glycolysis, and it is converted to HMG-CoA (3-hydroxy-3-methyl-glutaryl-coenzyme A), 
which is then reduced by HMG-CoA reductase to form mevalonate. Through a cascade 
reaction, cholesterol is ultimately produced. The cholesterol is then used in the essential 
synthesis of various hormones (estrogen, progesterone and testosterone) for maintaining 
internal homeostasis. One enzyme that inhibits the synthesis of estrogen specifically is the 
aromatase inhibitor, which inhibits the aromatase that transitions testosterone into estrogen. 
Estrogen, as aforementioned, is involved in cell proliferation and differentiation. Therefore 
by inhibiting the synthesis of estrogen, it is in-turn inhibiting cell proliferation and induces 
cell death (Billig et al., 1993; Lippman et al., 1976).  
Since, it has been established that cholesterol is the precursor of various hormones including 
estrogen and progesterone (Evans, 1988). Consequently, cholesterol concentrations are higher 
in BC cells compared to normal cells (Cruz et al., 2013; Mostaghel et al., 2012). The excess 
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cholesterol is used to maintain the rapid production of estrogen for the continual support of 
cancer cell proliferation (Buchwald, 1992; dos Santos et al., 2014). Cholesterol is naturally 
produced by the body through the mevalonate pathway (Fig. 1.3). It is a lipid molecule that is 
exclusively biosynthesised by all animals (WHO, 2018). In humans, cholesterol poses three 
main functions. Firstly, as previously mentioned, cholesterol is involved in the synthesis of 
various steroid sex hormones, and cortisone-like hormones in response to stress (Isaacsohn, 
1992). In addition, it is involved in the production of bile in the liver for the digestion of fats 
(Isaacsohn, 1992). Most importantly, cholesterol is found in all animal cell membranes and 
maintains cell stability and shape by forming lipid rafts (Isaacsohn, 1992). Since cholesterol 
is semi-soluble in aqueous conditions it is thus restricted from circulating throughout the 
body in the blood stream (hydrophilic) (Isaacsohn, 1992). Therefore, cholesterol molecules 
are encapsulated in water-soluble protein coats, known as lipoproteins that aid in the 
distribution of cholesterol as well as the reverse cholesterol transport (RCT) process (Fielding 
and Fielding, 1995). There are four types of lipoproteins namely: chylomicrons, very low-
density lipoprotein (VLDL), low density lipoproteins (LDL), and high density lipoprotein 
(HDL), where LDLs and HDLs are the main cholesterol carriers (Cruz et al., 2013; 
Isaacsohn, 1992).  
 
1.6 Intracellular and Extracellular Cholesterol Homeostasis  
Cholesterol homeostasis (Fig. 1.4) is a complex process regulated by several proteins; 
intracellular (proteins and enzymes) and extracellular (lipoproteins and CETP mechanisms) 
(Fig. 1.4) (Cruz et al., 2013). Extracellularly, free cholesterol synthesized from liver 
hepatocytes is transported to various cells via LDLs to cell surface receptors; LDLRs, where 
it is used to maintain cell membrane stability (Fielding and Fielding, 1995). Intracellular 
excess cholesterol is then converted to CEs by acyl-CoA: cholesterol acyltransferase (ACAT) 
in the endoplasmic reticulum and stored as lipid droplets (Fig. 1.4) (Fielding and Fielding, 
1995; Lin et al., 1999; Willner et al., 2003). In addition, intracellular cholesterol levels are 
maintained by the sterol regulatory element-binding proteins (SREBPs) (Fig. 1.4). SREBPs 
are endoplasmic reticulum membrane proteins that are part of the transcription factor family 
involved in cholesterol synthesis (Weber et al., 2004). SREBP forms a complex with the 
SREBP cleavage-activating protein (SCAP) (Horton et al., 2002; Ikonen, 2008; Nelson et al., 
2014), which acts as both a cholesterol sensor as well as a chaperone. In a cholesterol-poor 
environment, SCAP transports SREBP to the golgi body and undergoes several proteolytic 
activities and subsequently signals for cholesterol synthesis (Horton et al., 2002; Iddon et al., 
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2001). On the contrary, if cholesterol levels rise, SCAP prevents the movement of SREBPs 
and confines it in the endoplasmic reticulum (Horton et al., 2002; Iddon et al., 2001). An 
additional protein involved in intracellular cholesterol homeostasis is CETP. The human 
CETP gene, encodes a 74 kDa CETP protein, containing approximately 476 amino acids 
(Morton and Izem, 2014; Takahashi et al., 1993). CETP is found on chromosome 16q13 with 
a total of 17 exons (NCBI, 2018). The main function of CETP is CE and triglyceride 
transport in the plasma, however intracellularly, CETP protein has been shown to translocate 
CEs from endoplasmic reticulum to storage droplets or lipid droplets where CEs are stored. 
This is due to the fact that free cholesterol is cytotoxic to cells (Esau et al., 2016; Lagrost, 
1994). Moreover, CETP-deficient cells have been found to have lower levels of cholesterol, 
which could possibly be due to the accumulation of CEs within the endoplasmic reticulum. 
This accumulation could possibly signal for the down-regulation of proteins involved in 
cholesterol synthesis and possibly increase or upregulate proteins involved in the cholesterol 
clearance pathways (Esau et al., 2016; Lagrost, 1994).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Intracellular and extracellular transportation of cholesterol 
Free cholesterol is transported to cells via LDL and LDLR interactions. LDLs are then 
broken down by lysosomes into cholesterol and amino acids. The cholesterol is then used in 
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cell membrane stability or converted to CEs by ACAT and stored as lipid droplets mediated 
by CETP. Furthermore, SREBP regulate intracellular cholesterol synthesis and uptake 
between the endoplasmic reticulum and golgi body. Several proteins and receptors such as 
ATP-binding cassette transporters (ABCA1), scavenger receptor class B type 1 (SR-B1) and 
caveolins maintain intracellular cholesterol homeostasis. Internal or cellular toxicity is 
regulated through the coupling of p-glycoprotein (P-gp) to ABCA1, which transports drugs to 
the extracellular matrix. Therefore, ABCA1 is an important protein involved in multi-drug 
resistance (MDR). In addition MDR occurs when there is an increase in caveolin (red 
arrow), which increases membrane cholesterol. Extracellular cholesterol homeostasis is 
maintained by lipoproteins; HDL and LDLs. Cholesterol is cleared either directly through 
HDLs which interacts with SR-B1 to be excreted by the liver or indirectly, whereby CEs are 
shuttled by CETP from HDLs to the LDLs, which bind to LDLRs on hepatocytes for 
cholesterol clearance.  
One key player in intracellular cholesterol homeostasis is ABCA1 (family of ATP-binding 
cassette transporter) (Kang et al., 2013; Yvan-Charvet et al., 2010). ABCA facilitates the 
transfer of excess cholesterol (in the presence of P-gp) from the inside of cells to HDLs and 
apolipoprotein A-I (ApoA-I) that are outside of the cells, where cholesterol esterification 
occurs through lecithin: cholesterol acyltransferase (LCAT) (Fig. 1.4) (Tall et al., 2008). 
More importantly, overexpression of ABCA1 protein is involved in MDR, where it assists in 
the export of various hydrophobic compounds such as TAM (Dean et al., 2001), therefore 
reducing intracellular cytotoxicity. Overexpression of ABCA1 can be stimulated by LXR 
(liver X receptor), a nuclear membrane receptor that contains DNA-binding and ligand 
binding domains (Li et al., 2007). The interaction between a ligand (lipophilic molecules) and 
the receptor is followed by a conformation change in LXRs, which initiates coactivators for 
transcription of various target genes, one of which includes the gene encoding for ABCA1 
(Li et al., 2007). Therefore, the activation of LXR is directly proportional to cholesterol 
availability; where increased intracellular cholesterol enhances LXR activity and 
subsequently escalates ABCA1 expression and thus aids in the RCT process (Li et al., 2007). 
Furthermore, MDR is associated with high levels of caveolin-1 protein (a membrane protein 
specialising in lipid raft formation that are rich in signalling molecules, receptors, effector 
proteins, transducers) as increased level of this protein enhances cholesterol efflux (Fu et al., 
2004; Ho et al., 2008; Lavie and Liscovitch, 2000). In contrast to the unidirectional 
cholesterol transport of ABCA1 and caveolin-1, SR-B1 is an additional membrane protein 
that enables bidirectional, gradient-dependent transfer of free cholesterol (both cholesterol 
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efflux as well as influx) (Ohashi et al., 2005; Rosenson et al., 2012; Yancey et al., 2003). 
Moreover, SR-B1 mediates selective uptake of CEs, phospholipids and triglycerides in the 
RCT system, thereby maintaining cholesterol homeostasis both intracellularly and 
extracellularly (Yancey et al., 2003).  
 
Cholesterol clearance in the plasma is mostly maintained through lipoproteins in the RCT 
process. Excess cholesterol in the plasma is removed via HDLs either directly or indirectly 
(Fig. 1.4). Directly, HDLs transport CEs to the SR-B1 located on the liver to be excreted 
(Fig. 1.4). Indirectly, RCT is mediated by an important protein; CETP, where CETP aids in 
the shuttling of CEs and triglycerides from HDLs to LDLs and ultimately to the liver through 
the LDLRs (Fig. 1.4) (Agerholm-Larsen et al., 2000; Lagrost, 1994; Ohashi et al., 2005). The 
equilibration of cholesterol through CETP is crucial as lipid imbalance may lead to the 
development of cholesterol-related diseases and may affect normal brain functions. As 
previously mentioned, CETP deficient cells decreases CE levels inside the cell, 
extracellularly however, HDL levels appear to increase while LDLs decrease in the absence 
of CETP (Clark et al., 2004; de Grooth et al., 2004).  Subsequently, the raised HDL levels in 
the plasma suggest enhanced direct removal of plasma cholesterol (Esau et al., 2016; Lagrost, 
1994). Therefore, the concept of inhibiting CETP has been investigated as a possible 
therapeutic strategy in treating arthrosclerosis, cardiovascular disease and possibly 
Alzheimer’s disease (Bisgaier and Newton, 2001; de Grooth et al., 2004; Masson, 2009; 
Shinkai, 2012). Torcetrapib is one of the most well-known CETP inhibitors studied as a 
potential drug to treat artherosclerosis and lipid-related diseases by inhibiting CETP and 
increasing HDL levels (Bots et al., 2007; Clark et al., 2004). Despite the increase in HDL 
levels, the negative effects of torcetrapib have been shockingly concerning, these included: 
increased blood pressure, increased cardiovascular events and no significant decrease in 
coronary artherosclerosis risks (Barter et al., 2007; Bots et al., 2007; Forrest et al., 2008; 
Nissen et al., 2007). Due to the toxicity and off-target effects of torcetrapib, further research 
was terminated, which warrants alternative strategies to treat cholesterol-related diseases. In 
addition, the relationship of CETP in the context of cancer has never been investigated. 
Therefore, in this study, we aimed to knock-down CETP with small interfering RNA 
(siRNA) to observe the effect on cancer cells (due to positive correlation between cancer and 
cholesterol content). As aforementioned, it was found that CETP-deficient cells have lower 
CE levels hence our hypothesis whereby CETP knock-down and the use of a cholesterol 
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depleting agent after chemotherapeutic drug treatment could possibly be an alternative 
therapeutic advancement in reducing cancer-related drug resistance. 
 
1.7 Targeting Cholesterol for Cancer Treatment 
There are currently two approaches that target cholesterol as a possible therapy to treat BC; 
1) to block cholesterol synthesis using drugs such as statins, bisphosphonates, Lapaquistat 
and Lamisil (Fig. 1.5), and 2) to deplete excess membrane cholesterol using cholesterol-
depleting agents (Fig. 1.5).  
 
1.7.1 Cholesterol synthesis inhibitory drugs  
In light of the accumulation of excess cholesterol in cancer cells for cell proliferation and 
survival, a vast number of studies have investigated the use of cholesterol synthesis inhibitory 
drugs (Isaacsohn, 1992; Mostaghel et al., 2012; NIH, 2016). The most well known of these 
drugs includes the family of statins (Mostaghel et al., 2012). Statins are HMG-CoA reductase 
inhibitors that impede the function of this enzyme involved in the conversion of acetyl-CoA 
to HMG-CoA, thereby stunting the mevalonate pathway (Stancu and Sima, 2001). This 
consequently, decreases cholesterol levels and thus have shown to be effective in the 
treatment of arthrosclerosis and coronary heart disease (Stancu and Sima, 2001). Moreover, 
the hindrance of cholesterol synthesis negatively impacts on cancer cells by halting the 
production of growth hormones (Hoque et al., 2008). Evidently, statins have been observed to 
have the ability to impair cell growth by down-regulating growth-promoting signals 
involving RAS, PI3K/AKT, Wnt/β-catenin signalling cascades and induce proapoptotic 
signalling pathways in various cancer cells to increase apoptotic potential (Ampuero and 
Romero-Gomez, 2015; Tsubaki et al., 2011). Despite the significant anticancer properties, 
there have been several adverse side effects associated with statin use. These side effects may 
be fatal and include: myopathy, idiopathic polyneuropathy and at times, the onset of 
developing dementia as cholesterol is vital for normal brain functions (Moosmann and Behl, 
2004; Sinzinger et al., 2002). The use of statins and its effects on cancer development have 
been controversially discussed for decades (Boudreau et al., 2010; Hindler et al., 2006). 
Several studies have shown that statins possess anticancer properties (Campbell et al., 2006; 
Chan et al., 2003; Goard et al., 2010; Van Wyhe et al., 2017). However, numerous studies 
have also emerged that suggest statins actually promote the growth of cancer (Boudreau et 
al., 2010; Duncan et al., 2005; Fujimoto et al., 2015; Goldstein et al., 2008; Ravnskov et al., 
24 
 
2015). Therefore, it is crucial to improve the knowledge on the various effects of statins. An 
alternative to statins are bisphosphonates, which also blocks the synthesis of cholesterol in 
the mevalonate pathway (Fig. 1.5). However, bisphosphonates have been associated with the 
development of osteonecrosis (Kennel and Drake, 2009). Therefore, it is crucial to study the 
feasibility of blocking cholesterol synthesis as a therapeutic approach.  
 
1.7.2 Cholesterol-depleting agents  
On the contrary, due to the high level of cholesterol in cancer cells, especially in ER+ BC 
cells, depleting the excess cholesterol or disrupting the lipid rafts has been anticipated as an 
alternative or better method in treating BC, as well as cholesterol-related diseases. Increasing 
evidence has proposed that depleting cholesterol in the lipid rafts disrupt cell membranes and 
thus initiates apoptosis (Esau et al., 2016). Additionally, the removal of excess cholesterol 
within cell membrane induces chemosensitivity to certain drugs, such as TAM (Mandal and 
Rahman, 2014; Mohammad et al., 2014).   
Methyl-β-cyclodextrin (MβCD) is amongst the most extensively studied cholesterol-
depleting agents, which has shown significant anticancer activity in a number of cancers 
including BC (Fig. 1.5) (Mohammad et al., 2014), by effectively decreasing membrane 
cholesterol through lipid raft disruption (Ahern et al., 2014). MβCD is a well-studied 
cyclodextrin compound that possesses a hydrophobic cavity, which allows the extraction of 
cholesterol from cell membranes (Zidovetzki and Levitan, 2007). Studies performed on BC 
cells also showed that cholesterol-depletion by MβCD induced apoptosis in BC cells through 
down regulation of caspase-3 activation as well as Akt activity  (Li et al., 2006). In addition, 
MβCD was shown to increase the efficacy of TAM treatment by increasing its cholesterol 
uptake (Mohammad et al., 2014). The structures of membrane microdomains are essential for 
the modulation of the influx and efflux of cancer drugs (Mohammad et al., 2014). Therefore, 
cholesterol-depletion in the membrane disrupts lipid raft integrity and simultaneously 
increases membrane permeability for drug passage (Mohammad et al., 2014). Although 
MβCD has been shown to be less toxic as compared to most drugs, it is not cancer specific 
and thus it negatively impacts on normal cell proliferation (Mahammad and Parmryd, 2015). 
Recently, a new cholesterol depleting agent: acetyl-plumbagin (AP) has emerged and 
currently being investigated (Fig. 1.5). AP is a derivative of the highly toxic cholesterol-
lowering agent: plumbagin (PL) (Sagar et al., 2014). In several studies, PL has been found to 
induce apoptosis by a number of pathways. These include; signalling the production and 
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release of radical oxygen species (ROS) and NF-κB (nuclear factor kappa-light-chain-
enhancer of activated B cells), thereby inhibiting the activation of cyclin D to induce 
apoptosis (Sagar et al., 2014; Sandur et al., 2006; Srinivas et al., 2004; Wang et al., 2008). 
Due to the high toxicity of this molecule, various derivatives of PL were developed, one 
being AP (Sagar et al., 2014; Sakao et al., 2009). AP was observed to be several fold less 
cytotoxic compared to PL, especially in normal fibroblasts both in-vitro and in-vivo (Esau et 
al., 2016). Though the exact mechanisms of AP have not been well studied, the depletion of 
cholesterol using AP resulted in a decrease in CETP mRNA expression, as well as a 
significant increase in mitochondrial mediated apoptosis (Esau et al., 2016). However, due to 
a decrease in CETP mRNA expression that was observed, we thus speculate that by 
knocking-down CETP along with the use of a cholesterol-depleting agent (such as AP) in 
combination with a chemotherapeutic drug could possibly increase cytotoxicity in cancer 
cells. Thus, this could serve as an alternate therapeutic strategy in treating BC or cholesterol-
related diseases. It would also be interesting to see if CETP knock-down could result in 
increased efficacy of chemotherapeutic drugs and reduce resistance. However, this is a 
completely novel concept and thus requires understanding of the basic role of CETP in 
cancer. In this study, we have attempted to study the effects of CETP knock-down on cell 
growth and apoptosis with or without drug treatment. 
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Currently, several drugs targeting cholesterol synthesis pathways have been developed. 
These drugs include: statins, bisphosphonates, lapaquistat and lamisil. In addition, the 
cholesterol-depleting agents such as MβCD, AP and aminonaphtoquinones (unpublished 
results) have been verified to target excess cholesterol to cause cell death. Furthermore, the 
proliferative pathways, that have been mentioned previously; RAS, PI3K/Akt, Wnt/SHH 
pathway and AMPK (activated protein kinase) pathway, could have been affected. Moreover, 
CETP with the use of a cholesterol-depleting agent, simultaneously, resulted in an increased 
cell death.  (Esau et al., 2016). 
Figure 1.5: Targeting cholesterol as a possible therapeutic approach 
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1.8 Preliminary Studies on CETP 
Preliminary results from Professor Kaur's previously published work (Esau et al., 2016) 
showed that downregulation of CETP mRNA expression and the use of cholesterol depleting 
agents (AP, MβCD) resulted in the inhibition of growth and induced an increase in 
mitochondrial-mediated apoptosis of cancer cells. In addition, it was also shown that caspase-
3/7 activity in MCF-7 cells (TAM-treated) increased significantly when CETP was knocked-
down (Esau et al., 2016). Therefore, using the preliminary results, we hypothesised that 
CETP mRNA expression can possibly be used as a therapeutic marker, more specifically as a 
drug-resistance marker for monitoring and modifying the chemotherapeutic effects of drugs 
such as: TAM and 5-FU.   
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2. Aims and Objectives 
2.1 Aim 
 To test CETP’s role as a potential drug-resistance marker during the treatment of BC cells 
with commonly used chemotherapeutic drugs. 
 
2.2 Objectives 
 To perform CETP knockdown on BC cells to observe how it enhances the effectiveness 
of chemotherapeutic drugs (TAM and 5-FU). 
 
 To measure changes in cholesterol content, more specifically CEs, before and after CETP 
knockdown in ER+ and ER- BC cell lines. 
 
3. Methods and Materials  
The following methods were performed on both the transfected and non-transfected cell lines. 
Each experiment was performed repeatedly (at least three times) for accurate and 
reproducible results. The drugs that were tested included- test compounds: TAM (Sigma 
Aldrich, UK) and 5-FU (Sigma Aldrich, UK), and control compounds: PL (Sigma Aldrich, 
UK) or AP (synthesized from the Chemistry Department, University of the Witwatersrand) 
and MβCD (Sigma Aldrich, UK) in four different concentrations (5 µM, 10 µM, 20 µM and 
40 µM).  
 
3.1 Cell Culture  
All cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma Aldrich, 
UK and Gibco: Life Technologies, UK) with varying concentrations of foetal bovine serum 
(FBS) (Celtic Molecular Diagnostics, SA; Biowest, UK) (Table 1), 1% penicillin-
streptomycin (P-S) (Sigma Aldrich, UK) and incubated at 37 °C and 5% carbon dioxide 
(CO2) incubator to mimic in-vivo conditions.  
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Table 1: Cell lines used for the research with the respective FBS concentrations 
 MCF-7 MDA-MB 231 HEK 293 
Full Name Michigan Cancer 
Foundation-7 
M.D. Anderson Metastatic 
Breast Cancer  
Human embryonic 
kidney cells 
Receptors BC cell (ER+) Triple Negative BC cells ER negative 
Morphology/ Type Epithelial Epithelial Epithelial 
Disease  Adenocarcinoma, 
breast mammary 
gland 
Adenocarcinoma, breast 
mammary gland 
 
- 
Growth mode Adherent Adherent Adherent 
Media DMEM,10%FBS, 
1% P-S 
DMEM, 5%FBS, 1% P-S DMEM, 10%FBS, 1% 
P-S 
 
3.2 Cell Counting  
A Neubauer haemocytometer was used to count cells in order to seed the accurate number of 
cells in each well. A haemocytometer is a counting chamber that uses a grid method on a 
glass slide to predict an estimated total number of cells in the flasks. Prior to cell counting, 
media was removed and 2 ml of 1 X trypsin/EDTA (Sigma Aldrich, UK; Celtic Molecular 
Diagnostics, SA) was added into the flask and incubated at 37 °C for the activation of trypsin 
to allow cells to be detached. Once cells were detached, 100 µl of media containing cells was 
added to the same amount of 0.4% trypan blue (Sigma Aldrich, UK) and mixed thoroughly. 
Trypan blue is the most commonly used dye that stains the dead cells blue due to disrupted 
membrane and leaves the live cells unstained as intact cell membrane prevents the trypan 
blue from entering the cells. Thereafter, 10 µl of the mixture was added onto the 
haemocytometer and cells were counted under the microscope. Both live and dead cells were 
counted in the four outer quadrants (A, B, C and D in Fig. 3.1). In addition, cells on the top 
and right lines (indicated in red lines) of the outer edges of the 16 squares were also included 
in the count. 
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% cell viability = number of dead cells (unstained)     x    100 
           Total cells counted (dead and live) 
45 µl x total number of wells = total volume of media required (a) 
5000 cells/ well x total number of wells = total number of cells required  
 
Total volume in flask (µl) x total number of cells required  
Total number of cells counted in flask  
= volume of cells required from flask (b) 
 
a - b = media to be added to cells  
45 µl was then pipetted into each well with approximately 5000 cells/well 
 
 
 
 
 
 
 
 
Cellular viability was calculated as follows:  
 
 
Cellular viability measures the number of viable or live cells in the flask that can be used in 
further experiments and cell viability above 95% was used for further experiments. 
Cells were then seeded at a desired density as follows: 
 
 
 
 
 
 
 
 
Figure 3.1: Haemocytometer; Cell Counting Chamber 
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3.3 Growth Inhibition Assay  
MTT (3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma Aldrich, UK) 
assay was performed to measure the effect of each drug or compound with varying 
concentrations (5 µM, 10 µM, 20 µM and 40 µM) as well as combination treatment of 40µM 
TAM with AP (5 µM, 10 µM, 20 µM) on cell viability (Sagar et al., 2014) for 24 hours (hrs). 
PL (40 µM) was used as a positive control as it is a well-known compound to cause growth 
inhibition (Esau et al., 2016). MTT assay is a colorimetric assay that measures the reduction 
of MTT/tetrazolium salt by metabolically active cells and results in the formation of 
formazan crystals. Cells were seeded into a 96-well plate at a density of 5 000 cells/well and 
incubated at 37 °C for 20 - 24 hrs. MTT (5mg/ml in phosphate buffered saline (PBS) (Sigma 
Aldrich, UK)) was added for 2 hrs and the formazan crystals were subsequently dissolved in 
solubilising solution (10% SDS (sodium dodecyl sulphate) (Sigma Aldrich, UK) with 10mM 
hydrochloric acid (HCl)) for at least 16 hrs. The optical density (OD) was subsequently 
measured at 570 nm using a microtiter plate reader-Multiskan GO Microplate Reader 
(Thermo Fisher Scientific, SkanIt
TM
 software) and the percentage of cell growth inhibition 
was calculated in Microsoft Office Excel
© 
(formula shown below). 
 
  
 
 
3.4 Apoptosis Assay  
APOPercentage (APO%) assay was performed using the APO% assay kit (Biocolor, UK) to 
observe apoptosis post drug treatment (same treatments as in MTT assay). APO% assay 
detects the early stages of apoptosis in adherent cells. The APO% dye enters cells that are 
undergoing apoptosis where during this process the scramblase enzyme inactivates flippases 
(under normal circumstances flippases maintains the membrane structure) causing a 
membrane flip (Fig. 3.2) (Biocolor, UK).  
Average of absorbance values of test samples - Average of absorbance values of blanks (a) 
% Cell Viability =   [(a) of test ÷ (a) of untreated] × 100 
% Growth Inhibition = 100 - % Cell Viability 
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(Image adopted from: www.biocolor.co.uk) 
Cells (5 000 cells/well) were seeded into 96-well plate and incubated at 37 °C for 20 - 24 hrs. 
Thereafter, cells were treated with drugs/compounds for 2 hrs as the assay detects the 
beginning stages of apoptosis. Drug treatment for more than 2 hrs may lead to detachment of 
cells and thus risk of being washed off resulting in inaccurate readings. Media was removed 
from each well and 65 µl of dye mix (0.5 µl of APO% dye and 64.5 µl 1 X PBS) was added 
to each well. The plate was then incubated at 37 °C for 20 - 30 minutes (min). Subsequently, 
each well was washed gently with 100 µl of 1 X PBS. Lastly, 100 µl of 1X PBS was added to 
prevent the cells from drying out. The plate was then measured at 550 nm using a microtiter 
plate reader-Multiskan GO Microplate Reader (Thermo Fisher Scientific, SkanIt
TM
 software) 
and the percentage of cells undergoing apoptosis was calculated in Microsoft Office Excel
© 
(formula shown below). 
 
 
 
Figure 3.2: APO% Assay; Mode of Action 
Average of absorbance values of test samples - Average of absorbance values of blanks (a) 
% Cell Death = [(a) of experimental – (a) of untreated] ÷ (a) of untreated × 100  
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3.5 Transfection (CETP knock-down) 
Transfection is the process of manipulating the expression of a particular gene by introducing 
foreign nucleic acids such as plasmid DNA or RNA (siRNA) into eukaryotic cells. The 
siRNA technique is most commonly used for reducing gene expression post-transcriptionally 
by degrading mRNA. The siRNAs are small interfering RNAs that are approximately 20 - 25 
base pairs. They are double stranded RNAs that interfere with gene expression of target 
sequences. The siRNA bind to argonaute or RNA-induced silencing complex. Argonaute 
prevents elongation factors from binding to the RNA and recruits RNA-induced silencing 
complex (RISC), which prevents interaction between 60S and 40S (RNA subunits). The 
siRNA-RISC complex then binds its complementary sequence and silences target genes (Fig. 
3.3) (Dharmacon™, GeLifesciences, SA). 
 
 
 
 
 
 
 
 
 
 
(Image adopted from: http://mcmanuslab.ucsf.edu/node/268) 
 
For this project, CETP was knocked-down using the Silencer
® 
Select Pre-designed CETP 
siRNA (Ambion
®
, Life Technologies, USA) and the lipid-mediated DharmaFECT™ 
Transfection Reagent (Dharmacon™, GE Healthcare, UK; Inqaba Biotec™). Cells were 
seeded into a 6-well plate at a density of 50 000 cells/well (MCF-7) and 10 0000 cells/well 
(HEK293 and MDA-MB 231) in triplicates for at least 20 hrs. HEK 293 and MDA-MB 231 
Figure 3.3: siRNA; Mode of Action 
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cells were plated at different cell densities to account for cells that do not re-attach on plate 
surfaces as they are highly sensitive. The cells were then transfected as follows: 
 
Table 2: Volumes of siRNA and transfection reagent per well to make up a final siRNA 
concentration of 25 nM 
   Tube 1: siRNA/ siRNA 
negative control 
(µl/well) 
Tube 2: 
DharmaFECT™reagent 
(µl/well) 
 
Cell Type  Cell 
Density 
Complete 
medium 
(µl) 
Volume of 
5 µM 
siRNA (µl) 
Serum-free 
medium 
(µl) 
Volume of 
DharmaFECT™
reagent (µl) 
Serum-free 
medium 
(µl) 
Total 
volume per 
well (µl) 
MCF-7 5 x 10
4 
1 600 10 190 1 199 2 000 
MDA-
MB-231 
1 x 10
5
 1 600 10 190 2 198 2 000 
HEK293 1 x 10
5
 1 600 10 190 2 198 2 000 
 
In tube 1, the required amount of 5 µM siRNA/siRNA negative control was added to serum-
free media and in tube 2, DharmaFECT™ reagent was added to the recommended serum-free 
media as shown in Table 2. The tubes were allowed to sit at room temperature for 5 min and 
thereafter, contents of tube 2 were added and mixed to tube 1 making up a total volume of 
400 µl. The siRNA and DharmaFECT™ reagent mix in tube 1 was then incubated at room 
temperature for 20 min to allow the transfection reagent to encapsulate the siRNA. 
Subsequently, this mixture was then added to each well making up a total volume of 2 000 
µl/well. Cells were transfected for 72 hrs before harvesting/ plating of cells for downstream 
applications.  
 
3.6 To confirm successful transfection 
Western blotting and quantitative polymerase chain reaction (qPCR) was carried out to 
confirm successful knock-down of CETP. 
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3.6.1 Western Blotting  
Transfected and non-transfected cells were harvested (multiple wells were combined with at 
least 10
6 
cells/well) and pelleted at 4 000 x g for 5 min. The supernatant was removed and 1 
X Ripa or lysis buffer was added (100 µl/10
6
 cells). Lysis buffer disrupts the cell membrane 
thus releasing the internal proteins and components of the cell. The protein concentrations of 
each cell sample were measured using a BCA (bicinchoninic acid) assay.  
Table 3: Lysis Buffer component 
 Component (for 100 ml) 
1 X Ripa/ Lysis buffer  300 mM NaCl = 0.876 g 
 1% Triton-X-100 = 1 ml 
 1% Deoxycholate = 1 g 
 0.1% SDS 1 ml of 10% SDS 
 50 mM Tris = 1.21 g 
 10 mM EDTA = 1 ml 
(All reagents from Sigma Aldrich, UK) 
 
- Protein Quantification: BCA Assay 
 BCA assay is a technique based on the reduction of copper sulfate (Cu
2+
) to Cu
+
 (in 
the presence of protein), which interacts with BCA resulting in the development of 
purple colour that is measured spectrophotometrically (Smith et al., 1985; Walker, 
1994). Protein concentrations of unknown samples may then be determined by 
comparing with a known protein standard (example shown below in Fig. 3.4). Protein 
quantification is essential to ensure equal loading during SDS-PAGE (sodium dodecyl 
sulfate polyacrylamide gel electrophoresis). A BSA (bovine serum albumin) 
(Amresco; Inqaba Biotec™, SA) standard curve was generated using the following 
BSA concentrations; 1 mg/ml, 0.8 mg/ml, 0.6 mg/ml, 0.4 mg/ml, 0.2 mg/ml and 0 
mg/ml as blank and 25 µl of each concentration was added to a 96-well plate in 
triplicates. The protein concentration of each lysate was determined by the addition of 
5 µl of protein lysate and 20 µl of 1 X lysis buffer into each well in triplicates. 
Thereafter, 200 µl of BCA reagent mix (196 µl of BCA (Sigma Aldrich, UK)) and 4 
µl of Cu
2+
 (Sigma Aldrich, UK)) was added into each well and the plate was 
incubated at 37 °C for 30 min. The plate was then measured at 562 nm using a 
microtiter plate reader-Multiskan GO Microplate Reader (Thermo Fisher Scientific, 
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SkanIt™ software) and the protein concentration of each lysate was calculated in 
Microsoft Office Excel
©
. 
 
 
 
 
 
 
 
 
 
BSA Protein Standard was created using 1 mg/ml, 0.8 mg/ml, 0.6 mg/ml, 0.4 mg/ml, 
0.2 mg/ml of BSA and 0 mg/ml as blank 
The concentrations of protein lysate were calculated as follows: 
 
 
- SDS-PAGE  
SDS-PAGE Gel was made with the following components: 
 
Table 4: SDS-PAGE gel (10%, 1 mm) components: 
 Resolving Gel Stacking Gel 
Resolving gel buffer with SDS 3 ml - 
Stacking gel buffer with SDS - 750 µl 
30% Bis-acrylamide (Sigma 
Aldrich, UK) 
3 ml 500 µl 
Distilled Water (dH2O) 3 ml 1.75 ml 
10% Ammonium Persulfate 200 µl 30 µl 
Average of samples – average of blank = (a) 
Substituted y-value with (a) in the y = mx + c formula above in BSA protein standard  
∴ Calculated x-value 
x-value × 5 (for dilution) = protein lysate concentration (mg/ml) 
Figure 3.4: BSA Protein Standard 
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(APS) (Sigma Aldrich, UK) 
Tetramethylethylenediamine 
(TEMED) (Sigma Aldrich, UK) 
20 µl 3 µl 
 
Table 5:  Buffer Components 
 Components 
Resolving Gel Buffer  36.2 g Tris 
 0.8 g SDS 
 Dissolve in 150 ml dH2O 
 pH to 8.9 
 Make up to 200 ml with dH2O 
Stacking Gel Buffer   5.9 g Tris 
 0.4 g SDS 
 Dissolve in 70 ml dH2O 
 pH to 6.8 
 Make up to 100 ml with dH2O 
30% Bis-acrylamide (Sigma Aldrich, UK)  30 g Acrylamide 
 0.8 g Bisacrylamide 
 0.1 g SDS 
 Make up to 100 ml dH2O 
10% APS (Sigma Aldrich, UK)  100 mg APS in 1 ml dH2O 
 
Lysates of equal volume were loaded onto the gel with the Precision Plus Protein™ 
unstained standards (Bio-Rad, USA) and run at a voltage of 120 V for 1 hr. Proteins 
were then transferred onto a 0.22 µM PVDF (Polyvinylidene fluoride or 
polyvinylidene difluoride) membrane using the Trans-Blot
®Turbo™ Transfer System 
(Bio-Rad, USA). The membrane (containing the proteins) was then transferred into a 
3% BSA blocking solution for 1 hr to prevent non-specific binding. Primary 
antibodies (anti-CETP or anti-β-tubulin; loading control) were then added and 
incubated overnight at 4 °C. Thereafter, 5 X 5 min PBS washes were performed to 
wash off unbound antibodies followed by the addition of specific secondary 
antibodies and incubated at room temperature on the shaker for 1 hr. Subsequent PBS 
washes were performed and ECL substrate (horseradish peroxidase conjugated 
substrate – 1ml of reagent A and 1 ml of reagent B) was added. Membranes were 
viewed on the chemidoc (Bio-Rad, USA) and densitometry was performed using 
Image Lab™ 4.0 Software (Bio-Rad, USA).  
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3.6.2 Reverse Transcription - Quantitative Polymerase chain reaction (RT-qPCR) 
An alternative method, RT-qPCR, to confirm successful knock-down was employed. This 
method is a rapid and sensitive technique in determining and quantifying of nucleic acid 
biological samples after amplification, in this case mRNA expression in transfected and non-
transfected cells.  
- RNA Extraction 
RNA extraction was performed using the Direct-zol™ RNA MiniPrep kit (Zymo 
Research, Inqaba Biotec™, SA). TRIzol® reagent (300 µl) (Ambion®, Life 
Technologies, USA) was added to the cell pellet and mixed thoroughly for 5 min at 
room temperature; Trizol is a commonly used chemical reagent that breaks cell 
membranes for the isolation or extraction of intact RNA, DNA and proteins (Simms et 
al., 1993; Simões et al., 2013). Equal amount of 99.9% ethanol was added to the 
samples to precipitate the nucleic acids. The samples were then transferred to Zymo-
Spin™ IIC Column in a collection tube and centrifuged at 16000 x g for 30 seconds 
(s); as well as for subsequent centrifugation steps. The flow through was discarded 
and the column was washed with 400 µl RNA wash buffer. Thereafter, a DNase step 
(5 µl DNase I with 75 µl DNA digestion buffer) was added, and column was 
incubated at room temperature for 15 min to prevent DNA contamination during RNA 
extraction procedure. The sample in the column was then washed with 400 µl of 
Direct-zol™ RNA PreWash and again washed with 700 µl of RNA wash buffer. 
Finally, RNA was eluted and suspended in 50µl of DNase/RNase-Free water and 
stored at -80 °C (Direct-zol™ RNA MiniPrep kit; Zymo Research, Inqaba, SA). RNA 
quantification was performed using the Nanodrop 1000 spectrophotometer (Thermo 
Fisher Scientific, USA) to ensure that the RNA extracted was pure and intact for 
downstream applications. RNA samples with a 260/280 ratio between 1.9 and 2 were 
used for further experiments.  
- cDNA synthesis  
The RevertAidFirst Strand cDNA Synthesis kit (Thermo Fisher Scientific, USA) was 
used to convert isolated RNA to cDNA in preparation for qPCR. The following 
components were added to RNA template: 
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Table 6: Following reagents were involved in the cDNA synthesis process for a 20 µl 
reaction 
Reagent Volume (µl) 
Template RNA  2µg (volume dependent on RNA 
concentration) 
Oligo (dT)18 primer  1  
Nuclease-free water  Up to 12  
Total Volume 12  
Master Mix 
5X Reaction Buffer  4  
RiboLock RNase Inhibitor  1  
10mM dNTP Mix 2  
RevertAid M-MuLV RT (200U/µl) 1  
Total Volume 20 
 
The samples were mixed and centrifuged briefly prior to incubation at 42 °C for 1 hr 
using the MultiGene PCR machine (Labnet International, UK). The reaction was then 
terminated at 70 °C for 5 min and stored at -20 °C indefinitely.  
- RT-qPCR 
The SensiFAST™ SYBR® No-ROX kit was used to determine CETP mRNA 
expression in transfected and non-transfected cells. SYBR green is a cyanine dye that 
intercalates into double stranded DNA during the annealing and extension step. 
Consequently, SYBR green detection (Cq- initial detectable signal of SYBR green) is 
directly proportional to the amount of template and extension during RT-qPCR. The 
reaction was reduced to half therefore final volume of reaction mix is 10 µl and the 
components are shown below in Table 7.  
Table 7: qPCR reagent composition 
Reagent Volume (µl) Final Concentrations 
2X SensiFAST™ SYBR® No-ROX mix 5 1X 
10µM Forward Primer 0.4 400 nM 
10µM Reverse Primer 0.4 400 nM 
cDNA Template 2 - 
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dH2O 2.2 - 
Final Volume 10 - 
 
Primers were synthesised by Integrated DNA Technologies (IDT- Illinois, USA) and 
the sequences are shown in table 6. 
 
Table 8: Primer sequences of CETP and GAPDH genes 
Gene Sequence (5ʹ-3ʹ) Annealing 
Temperature (°C) 
GC Content 
(%) 
Ref. 
CETP (Forward) GAGTCCCATCACAAGGGTCA  
57.1 
55 Ding et 
al., 
(2015) 
CETP (Reverse) GGAAGACTCGCTCAGAGAACC 57.1 
GAPDH (Forward) CGTGTCGGTTGTGGATCTGA 55 
GAPDH (Reverse) TGACGAAGTGGTCGTTGAGG 55 
 
A 3-step cycling parameter was set on the AriaMx Real-time PCR System 
(Diagnostech; Agilent Technologies, SA) and samples were run in white, opaque 8-
well PCR strips (BIOPlastics, Netherlands; Celtic Diagnostics, SA). The change in  
mRNA expression was calculated using the 2
–∆∆Ct
 method (Livak and Schmittgen, 
2001). 
 
Table 9: The 3-step cycling parameters 
Cycles Temperature (°C) Time Step 
1 95 2 min Polymerase activation 
 
40 
95 5 s Denaturation 
57.1 10 s Annealing 
72 15 s Extension 
 
3.7 Cholesterol Assay 
Cholesterol assay was performed to measure the cholesterol content in the transfected and 
non-transfected cells with and without drug treatment, which was used to confirm whether 
the transfection as well as the drug treatment affected the cholesterol level in the cell.  
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(Image Adopted from: https://www.bioscience.co.uk/userfiles/pdf/STA-384-total-cholesterol-
colorimetric-assay-kit.pdf) 
Briefly this method involves the hydrolysis of CEs by cholesterol esterase, which forms 
cholesterol. Cholesterol is then oxidised by cholesterol oxidase that results in two products: 
1) cholest-4-ene-3-one and 2) hydrogen peroxide (H2O2). H2O2 is detected with a highly 
specific colorimetric probe (ampliflu red - Sigma Aldrich, UK), The HRP catalyses the 
reaction between H2O2 and ampliflu red that binds in a 1:1 ratio. This reaction results in the 
development of a pink colour, which is read at 570 nm (Sigma Aldrich, UK).  
Transfected and non-transfected cells were seeded in a 96-well plate at a density of 5 000 
cells/well in duplicates (as reagents are expensive) in two sets; one testing total cholesterol 
and free cholesterol in the other. The seeded cells were incubated at 37 °C for 20-24 hrs and 
treated with drugs for 24 hrs. The media was removed from each well and washed with 50 µl 
1 X PBS. Subsequently, 10 µl of 100 U/ml catalase (Sigma Aldrich, UK) to each well and 
incubated for 15 min at 37 °C. Catalase is an enzyme that is known to degrade excess H2O2 to 
water and thus protect cells from ROS also preventing background noise when measuring the 
absorbance. Reagent A was prepared using the following components: 
 
Figure 3.5: Principle of Cholesterol Assay 
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Table 10: Components for reagent A per well in this order 
Reagent A Total Cholesterol (with 
esterase) (µl/well) 
Free Cholesterol (without 
esterase) (µl/well) 
1 M Potassium phosphate 
buffer (KPO4)  
(Sigma Aldrich, UK) 
2.5 2.5 
1 M Sodium Chloride (NaCl) 
(Sigma Aldrich, UK) 
6.25 6.25 
100mM Cholic acid  
(Sigma Aldrich, UK) 
1.25 1.25 
100% Triton-X-100  
(Sigma Aldrich, UK) 
0.25 0.25 
20 U/ml cholesterol oxidase 
(Sigma Aldrich, UK) 
2.5 2.5 
150 U/ml HRP  
(Sigma Aldrich, UK) 
1.44 1.44 
25 U/ml cholesterol esterase 
(Inqaba Biotec™, SA)  
3.33 - 
Isopropanol:NP-40 (9:1) 
(Merck, SA) 
6.48 9.81 
10 mM Ampliflu Red  
(Sigma Aldrich, UK) 
1 1 
 
Following the 15 min. incubation with catalase, 25 µl of reagent A (with esterase and without 
esterase respectively) was added to the respective wells, mixed using plate shaker at 500 rpm 
and incubated, covered with foil, for 30 min. at 37 °C. The absorbance of each well was 
measured with the microtiter plate reader-Multiskan GO Microplate Reader (Thermo Fisher 
Scientific, SkanIt
TM
 software) and cholesterol concentration was calculated in comparison to 
the known cholesterol standards (5, 10, 15, 20 and 0 µg/ml as blank). CEs were calculated as 
follows:  
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3.8 Statistical analysis 
The statistical analyses were performed using Microsoft Office Excel
©
. The experimental 
procedures were performed in triplicates and repeated at least 3 times for reproducibility. 
Furthermore, the statistical significance was calculated using student’s t-test. A p-value of 
less than 0.05 was used to estimate the significance of the observations. A Z-factor (Zhang et 
al., 1999b) was calculated for each 96-well plate and assays having Z-factor above > 0.5 were 
included in the statistical analysis as it is the acceptable range in which the technicality of the 
experiments was trustworthy.   
 
 
 
Average of samples – average of blanks = (a) 
Substituted y-value with (a) in the y = mx + c formula above in the cholesterol standard 
curve 
∴ Calculated x-value for total cholesterol and free cholesterol 
x-value = cholesterol concentration (µg/ml)  
µg/ml converted to µg/µl → x-value ÷ 1000 × total volume in well = cholesterol 
concentration (µg/µl)  
Total cholesterol – free cholesterol = CE 
Figure 3.6: Cholesterol Standard Curve 
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3.9 Plan of work 
Due to the complexity of the project, the flow chart (Fig 3.7) outlines my work flow for this 
study, where red represents MDA-MB-231 cell line, blue representing MCF-7 cell line and 
green representing HEK 293 cell line (Fig. 3.7). Due to time constraints, only a limited 
number of experiments were completed for MDA-MB-231 and HEK 293 cells. MTT and 
APO% assays were performed on MCF-7 and MDA-MD-231 cells in the absence or presence 
of TAM, MβCD, 5-FU, AP, and PL. Only MTT assay was performed on HEK 293 cells. 
CETP knock-down experiments were performed in MCF-7 and MDA-MB-231 cells and 
knock-down was confirmed or quantified using Western blotting (protein) and RT-qPCR 
(mRNA). The transfected cells were again subjected to TAM, MβCD, 5-FU, AP, and PL 
treatment where MTT and APO% assay was performed in both MCF-7 and MDA-MB-231 
cells. Thereafter, the CE level was measured in transfected and non-transfected MCF-7 cells 
only. A combination treatment of various TAM concentrations with different concentrations 
of AP was performed in 
transfected and non-transfected 
MCF-7 and MDA-MB-231 
cells to see if CETP knock-
down would increase apoptosis 
in cancer cells. MTT and 
APO% assay for the 
combination treatment was 
performed in non-transfected 
MCF-7 and MDA-MB-231 
cells. However, MTT and 
APO% assay for the 
combination treatment was 
only performed in transfected 
MCF-7 cells only. In addition, 
results will be presented 
according to cell line. 
Supporting data will also be 
presented in the appendix. 
 
 
Figure 3.7: Flow Diagram of work plan 
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4. Results and Discussions  
Targeting cholesterol as a possible therapeutic strategy to treat cancer, more specifically BC, 
is a relatively new concept. Previous research (Esau et al., 2016) reported that knocking down 
CETP resulted in promising outcomes where CETP knock-down combined with a 
cholesterol-depleting agent (AP) increased apoptotic activity in cancer cells significantly 
while depleting cholesterol. Therefore, in the present work, CETP knock-down was 
performed to observe the effect on current BC drugs such as TAM and 5-FU as well as 
cholesterol depleting agents such as MβCD and AP while using PL as positive control. 
Combination treatment of the cholesterol-depleting agent AP with TAM was also performed 
to observe the effect before and after transfection. This will thus serve as baseline results for 
further investigations.  
 
4.1 CETP protein knock-down was confirmed using Western blotting and pPCR in 
MCF-7 cells 
In Fig. 4.1, a successful CETP knock-down was observed using Western blotting and 
densitometry.  
 
Figure 4.1: CETP protein was successfully knocked-down and confirmed by Western 
blotting in MCF-7 cells 
Fig. 4.1a illustrating protein bands from Western blotting using Chemidoc and Fig. 4.2b 
depicts the densitometry analysis in MCF-7 cells. Data represents the mean ± standard 
deviation S.D. (n=3), * P < 0.05.   
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Equal bands observed for β-tubulin at 50 kDa indicating equal loading of lysate which 
confirms knock-down of CETP (faint bands as compared to the non-transfected and siRNA 
negative control) (Fig. 4.1a). 4.1b) Densitometry revealed a significant knock-down of 
CETP; decreasing protein level by 60.5% relative to the non-transfected MCF-7 cells. 
 
 
 
 
 
 
 
 
In addition, CETP knock-down was also confirmed using qPCR. Data represents the mean ± 
S.D. (n=2). 
CETP mRNA expression level was successfully knocked-down by 63%.   
 
4.2 Growth Inhibition and Apoptosis analysis in transfected and non-transfected 
MCF-7 cells 
Following the successful knock-down of CETP, MTT assay was then performed on 
transfected and non-transfected MCF-7 cells to compare the effects of the various drug 
treatments on growth inhibition (Fig. 4.3). In addition, to observe whether CETP knock-down 
would cause increased cell death with reduced drug concentration (especially TAM) in cancer 
cells in the absence or presence of AP (Fig. 4.5). 
Figure 4.2: CETP mRNA expression level was successfully knocked-down and confirmed by 
qPCR 
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Fig. 4.3 depicts the comparison of growth inhibition, through the analysis of MTT assay. The 
transfected MCF-7 cells were compared to non-transfected MCF-7 cells after treatment with 
various concentrations (5, 10, 20 and 40 µM) of a) TAM, b) MβCD, c) 5-FU and d) AP. 40 
µM PL was used as a technical positive control.  Data represents the mean ± S.D. (n=3), 
where * P < 0.05, ** P < 0.001, *** P < 0.0001 and ns = not significant. All plates had a Z- 
factor > 0.5. 
CETP knock-down resulted in an increase in growth inhibition by 6%, 25% and 18% with 
respective TAM concentrations (5 µM, 10 µM and 20 µM) in transfected MCF-7 cells when 
compared to non-transfected MCF-7 cells (Fig. 4.3a). However, at 40 µM TAM decreased in 
growth inhibition. b) Growth inhibition also increased when treated with 20 µM and 40 µM 
MβCD (by 10% and 8% respectively) in transfected MCF-7 cells compared to non-
transfected cells. c) Furthermore, CETP knock-down also resulted in a significant increase in 
growth inhibition when treated with all concentrations, except 10 µM of 5-FU. d) 
Interestingly, CETP knock-down resulted in a significant increase in growth inhibition when 
treated with 40 µM AP only whereas at lower concentrations, CETP knock-down lead to a 
decrease in growth inhibition when compared to the non-transfected MCF-7 cells.   
a) 
c) 
Figure 4.3: CETP knock-down significantly increased growth inhibition in transfected 
MCF-7 
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The images Fig. 4.4 are a visual representation of the effects of various drug concentration 
treatments in non-transfected MCF-7 cells compared to the untreated MCF-7 cells presented 
in Fig. 4.3.  
It can be observed that with increasing concentrations of TAM, 5-FU and AP, MCF-7 cells 
appear to be progressively more stressed and more spherical in shape. In contrast, MβCD did 
not seem to have much effect on growth inhibition and cells appear to be healthy as compared 
to the positive control (pos. control) - 40 µM PL. Thus, these images confirm the results 
shown in Fig. 4.3.  
 
Previously, Esau et al, (2016) showed that CETP was found to assist ER+ BC (such as MCF-
7 cells) in cell proliferation, cholesterol uptake and thus been identified as a cell survival gene 
(Esau et al., 2016). Therefore, we show that in the absence of CETP, the treatment of various 
Figure 4.4: Visual representation of non-transfected MCF-cells when treated with various 
concentrations of drugs for 24 hrs 
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drugs impeded cancer cell growth and indicate a lowered cell survival rate as well as drug 
resistance (Fig. 4.3) with exception at 40 µM. However, this could suggest that high 
concentrations of TAM could possibly increase the expression of ABCA1 that assists the 
export of cytotoxic compounds. The increase in growth inhibition observed in Fig. 4.3a-d 
suggested that knock-down of CETP does indeed increase drug efficacy, especially at lower 
concentrations. This is significant as this would result in a reduced IC50, which is the 
concentration that induces 50% of cell growth inhibition or cell death (Miyoshi et al., 2003). 
As previously mentioned, TAM, is the most commonly used drug in the treatment of 
hormone responsive BC cells. TAM has been shown to induce a dose-dependent cytotoxicity, 
where it caused a 50 - 60% reduction in cancer cell survival at 10 µM for 24 hrs (Perry et al., 
1995; Zhang et al., 1999a). However, in our results, we only observed approximately 10% 
cancer cell growth inhibition in non-transfected MCF-7 cells at 10 µM for 24 hrs and a four-
fold increase in growth inhibition in transfected MCF-7 cells. This is possibly an indication 
that our MCF-7 cell lines are more resistant, yet still causing a 40% increase in growth 
inhibition in the absence of CETP. 
Interestingly, CETP knock-down resulted in a significant 8–10% increase in growth 
inhibition at 20 and 40 µM of MβCD. Although this increase seems low, MβCD is a known 
cholesterol-depleting agent that is relatively low in cytotoxicity and several studies have 
shown that it is only effective in concentrations that are greater than 2 mM (Grosse et al., 
1998; Li et al., 2006; Onodera et al., 2013). Therefore, we show that the absence of CETP 
increases the efficacy of MβCD, even at low concentrations (20 and 40 µM). This increase in 
efficacy in transfected MCF-7 cells may indicate that by knocking-down CETP with the use 
of a cholesterol-depleting agent, such as MβCD, increases cholesterol depletion and possibly 
induces membrane instability thus sensitizes cells to foreign compounds (Krause and Regen, 
2014; Yeagle, 1985). This membrane instability from knocking-down CETP may also 
explain the enhanced cell growth inhibition when treated with 5, 20 and 40 µM 5-FU. 
However, when cells were treated with 10 µM, there was a slight decrease in growth 
inhibition. This could possibly suggest that there was uneven loading of cell numbers in the 
wells. Therefore, the overall increase in growth inhibition when treated with a variety of 
drugs/compounds may suggest that CETP knock-down possibly reduced MDR by decreasing 
P-gp activity due to membrane fluidity or decrease in membrane cholesterol 
(Reungpatthanaphong et al., 2004).  
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AP is a cholesterol-depleting agent derived from PL and has been found to be less cytotoxic 
to normal cells while still effective in cancer cells (Sagar et al., 2014). In addition, AP treated 
cancer cells have been observed to reduce CETP mRNA expression by 35% (Esau et al., 
2016). In this study, we observed a decrease in cell growth inhibition in transfected MCF-7 
cells when compared to non-transfected MCF-7 cells at lower concentrations. There is no 
biological explanation available for this observation and warrants further investigations. In 
this study, there was an increase in growth inhibition in transfected MCF-7 cells at 40 µM. 
However, this concentration becomes too cytotoxic to cells therefore it was expected to 
decrease cell viability.  
 
Fig. 4.5 depicts the comparison of cell death, through the analysis of APO% assay. The 
transfected MCF-7 cells to non-transfected MCF-7 cells after treatment with various 
concentrations (5, 10, 20 and 40 µM) of a) TAM, b) MβCD, c) 5-FU and d) AP. 40 µM PL 
was used as a technical positive control.  Data represents the mean ± S.D. (n=3), where * P 
< 0.05, ** P < 0.001, *** P < 0.0001 and ns = not significant. All plates had a Z- factor > 
0.5. 
 
Figure 4.5: CETP knock-down increased apoptosis in transfected MCF-7 
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Subsequently, APO% assay was performed to observe the amount of apoptosis caused by the 
various drugs in non-transfected and transfected MCF-7 cell line.Although not significant, 
knock-down of CETP resulted in an increase in apoptosis when treated with a) TAM (by 10-
40% at different concentrations), b) MβCD (by 30-60%) and c) 5-FU (by 5-10%). This 
correlates with the results obtained from MTT (Fig. 4.3) as an increase of growth inhibition 
was observed in transfected MCF-7 cells compared to the non-transfected MCF-7 cells. The 
same was observed for AP in Fig. 4.5d, where no significant change in apoptosis percentage 
was noted except at 5 µM (shown in red box). Although there was no statistical significance, 
there is a 30% biological significance in the analysis. However, this could possibly due to the 
small absorbance values as the smaller the number the greater the chance for error.  
The images in Fig. 4.6 are a visual representation of the effects of various drug concentration 
treatments in non-transfected MCF-7 cells compared to the untreated MCF-7 cells presented 
in Fig. 4.5. 
Figure 4.6: Visual representation of APO% assay between transfected and non-transfected 
MCF-7 cells treated with TAM and AP 
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As observed above, increasing drug concentrations lead to a progressive increase in APO% 
dye intake and thus the cells appear more pink when compared to the untreated cells. 
Furthermore, transfected cells appear to have retained more dye as compared to the non-
transfected MCF-7cells with a direct relation to drug concentration. Therefore, confirms the 
resultes depicted in Fig. 4.5.  
 
APO% assay that the knock-down of CETP enhanced apoptotic activities when cells were 
treated with TAM, MβCD and 5-FU. Interestingly, at 5 µM  AP however, there was about a 
30% increase in apoptosis in transfected MCF-7 cells when compared to non-transfected cells. 
This correlates to the results obtained in (Esau et al., 2016), where CETP knock-down 
showed an increase in apoptosis. This is favourable as it was mentioned previously, lowered 
effective concentration would suggest a smaller IC50 value. This could possibly reduce 
adverse side effects that are usually associated with various drugs. Moreover, the increase in 
apoptosis is further supported by the Kaplan-Meier plots in Fig. 4.7 displaying a link between 
CETP expression and BC patient survival from four different databases (Esau et al., 2016). 
These databases depicted that a low CETP expression is associated with longer relapse-free 
survival as well as overall survival. In addition, ER+ BC was revealed to express more CETP 
compared to ER- BC and are less likely of long term survival (Esau et al., 2016; Sukkasem et 
al., 2016). 
 
  
 
 
 
 
 
 
 
a) 
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Fig. 4.7a and b are Kaplan-Meier plots of (a) relapse-free survival and (b) overall survival of 
BC patients stratified by median CETP expression in the PROGgene database (Esau et al., 
2016; Goswami and Nakshatri, 2013). The red line represents high CETP expression and 
green line represents low CETP expression.  
 
4.3 Measurement of cholesterol levels in transfected and non-transfected MCF-7 
cells 
Cholesterol assay was then performed to measure CE levels in non-transfected and 
transfected MCF-7 cells (objective 2).  
Figure 4.7: Kaplan-Meier Plot on relapse-free survival and overall survival 
b) 
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Fig. 4.8 illustrates the CE level, through the analysis of cholesterol assay. The transfected 
MCF-7 cells were compared to non-transfected MCF-7 cells before and after treatment with 
various concentrations of a) TAM, b) MβCD, c) 5-FU and d) AP. 40 µM PL was used as a 
technical positive control. 
We observed a 70-90% decrease in CEs across the various drug/compound treatment in 
transfected MCF-7 cells compared to the non-transfected cells. Interestingly, apart from a 
decrease in CEs in drug/compound treated cells, there was also a decrease in CEs in the 
untreated transfected MCF-7 cells (indicated in the red boxes in Fig. 4.8a). Therefore, this 
suggests that by knocking down CETP, intracellular CE levels also reduced. Samples were 
performed in duplicates due to financial constraints. In addition, CE levels decreased 
drastically in AP-treated transfected MCF-7 cells at 5 and 10 µM. This could possibly explain 
the increase in cell death observed in transfected MDA-MB 231 cells (Fig. 4.5). 
As aforementioned, cancer cells are rich in cholesterol and thus have an altered lipid 
metabolism maintained by SREBP and ACAT (involved in CE synthesis) (Peck and Schulze, 
2014). It has been found that an increased activity of SREBP have been associated with 
several cancers and SREBP inhibition halted cancer cell growth and proliferation (Peck and 
Schulze, 2014). Therefore, this decrease in CE level that we observed in transfected MCF-7 
cells could possibly suggest a reduced SREBP activity. In addition, the accumulation of 
intracellular CEs result in an escalated PI3K-dependent SREBP activity and thus fueling 
Figure 4.8: Representation of CE levels in non-transfected and transfected MCF-7 cells 
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cancer aggressiveness (Peck and Schulze, 2014; Yue et al., 2014). Thus, we speculate that the 
surge in cancer cell growth inhibition and apoptosis in transfected MCF-7 cells treated with 
various drugs and compounds could be due to a reduction in CEs thereby managing cancer 
aggressiveness and increasing response to toxic drugs or compounds. Furthermore, high 
levels of intracellular CEs have been found to be associated with drug resistance (Peck and 
Schulze, 2014). This is due to the fact that in normal cells, the excess cholesterol stops the 
SREBP and ACAT activity. However, in cancer cells, ACAT and SREBP are continuously 
producing CEs for storage and thus reducing intracellular toxicity (Peck and Schulze, 2014). 
Additionally, in (Reungpatthanaphong et al., 2004), it was found that P-gp activity (involved 
in  MDR) is directly correlated to cholesterol levels and a decrease in cholesterol level 
resulted in a reduced P-gp activity thus reducing drug resistance. For these reasons, the 
increased cell death in transfected MCF-7 cells that we observed could have been due to the 
drop in intracellular CE levels thus redcuing drug resistance.  
 
4.4 Analysis of growth inhibition and apoptosis in transfected and non-transfected 
MCF-7 cells before and after the combination treatment of TAM and AP  
In addition, MCF-7 cells were treated with various concentrations of TAM together with 
different concentrations of AP to observe the effect on growth inhibition and apoptosis. The 
combination treatment was performed to observe whether the efficacy of TAM can be 
increased, especially at low concentrations, while reducing TAM resistance. 
Fig. 4.9 illustrates the effects of combination treatment on growth inhibition, through the 
analysis of MTT assay. The transfected MCF-7 cells (a) were compared to the non-
transfected MCF-7 cells (b). The concentration of TAM is constant (5 µM) whereas the 
Figure 4.9: Representative of combination treatments (5 µM TAM with various AP 
concentrations) in comparison to single drug treatment in non-transfected MCF-7 cells and 
transfected MCF-7 cells 
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concentration of AP is varied (5, 10, 20 and 40 µM). 40 µM PL was used as a technical 
positive control.  Data represents the mean ± S.D. (n=3), where * P < 0.05, ** P < 0.001, 
*** P < 0.0001 and ns = not significant. All plates had a Z- factor > 0.5. 
Although, in the non-transfected MCF-7 cells (Fig. 4.9a), the combination treatment appear 
to have increased growth inhibition when compared to TAM single treatment, there was 
actually a decrease in growth inhibition when compared to AP single treatment. In the 
transfected MCF-7 cells (b) however, we observed an increase in growth inhibition about 
30% when compared to both single treatments. Therefore, the increase in the combination 
treatment observed in transfected MCF-7 cells is possibly due to an increased efficacy of 
TAM. Supporting data (other concentrations of TAM and AP) are in the appendix (Fig 8.1 
and 8.2).  
Fig. 4.10 illustrates the effects of combination treatments on apoptosis, through the analysis 
of APO% assay. The combination treatments were compared to single drug treatment (TAM 
or AP alone) in non-transfected MCF-7 cells. Similarly, the combination treatment was 
compared to the single treatment in transfected MCF-7 cells. The concentration of the 
combination treatment is composed of 5 µM TAM and varying concentrations of AP (5, 10, 
20 and 40 µM). 40 µM PL was used as a technical positive control.  Data represents the 
mean ± S.D. (n=3), where * P < 0.05, ** P < 0.001, *** P < 0.0001 and ns = not 
significant. All plates had a Z- factor > 0.5. 
Similar results were observed in APO% assay where in (Fig. 4.10a) non-transfected MCF-7 
cells, even though apoptosis appear to have increased in the combination treatment compared 
to TAM single treatment, when compared to AP single treatment not much difference was 
observed at lower concentrations. However, (b) in transfected MCF-7 cells, the combination 
treatment caused a 15-fold increase in apoptosis compared to both single treatments (shown 
Figure 4.10: Representative of the combination treatment (5 µM TAM with various AP 
concentrations) in non-transfected and transfected MCF-7 cells 
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in red box). Therefore, the increase in the combination treatment observed in transfected 
MCF-7 cells is possibly due to an increased efficacy of TAM. Supporting data (other 
concentrations of TAM and AP) are in the appendix (Fig. 8.3 and 8.4). 
CETP knock-down along with the use of a cholesterol-depleting agent, AP, and treating the 
cells with TAM did indeed increase the apoptosis compared to single treatment by 
approximately 15-fold even at low concentrations (5 and 10 µM). This is possibly due to a 
decrease in CEs from knocking-down CETP together with the use of a cholesterol-depleting 
agent resulting in increased vulnerability of cells to TAM. Therefore, this suggests that when 
the three treatments are combined, the efficacy of TAM increases. Moreover, it appears that 
cells are less resistant to TAM when CETP was knocked-down along with the use of AP. 
Therefore, CETP knock-down along with the use of a cholesterol-depleting agent could 
possibly reduce resistance and increase efficacy of TAM and potentially other 
chemotherapeutic drugs. This increase in drug efficacy would mean that the dose of highly 
potent drugs could be reduced without lowering its effects and ultimately reduce possible side 
effects.   
 
4.5 CETP protein knock-down was confirmed using Western blotting in MDA-MB 
231 cells 
These assays proved to be highly effective in hormone responsive or ER+ BC cells. 
However, the effects of knocking-down CETP together with the use of AP have never been 
studied before in a triple negative BC cell line (MDA-MB-231). Due to time constraints, only 
certain assays were performed on MDA-MB-231 cells, however further experiments will be 
performed during my PhD study.   
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Fig. 4.11a illustrating protein bands from Western blotting using Chemidoc and b) depicts 
the densitometry analysis in MDA-MB 231 cells. Data represents the mean ± standard 
deviation S.D. (n=3), ** P < 0.001.  
Densitometry analysis revealed a 63% decrease in CETP mRNA expression in MDA-MB 
231 cells.  
 
4.6 Growth Inhibition and Apoptosis analysis in transfected and non-transfected 
MDA-MB 231 cells 
Transfected and non-transfected MDA-MB 231 cells were then treated with the various drug 
concentrations and the effects of the drugs on growth inhibition and apoptosis was analysed.  
Figure 4.11: CETP protein was significantly knocked-down in MDA-MB 231 cells 
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Figure 4.12: Growth inhibition was not significantly affected by the knock-down of 
CETP in MDA-MB 231 cells 
Figure 4.12 shows comparative growth inhibition, through the analysis of MTT assay. The 
transfected MDA-MB 231 cells were compared to non-transfected MDA-MB 231 cells treated 
with a) TAM, b) MβCD, c) 5-FU and d) AP. 40 µM PL was used as a technical positive 
control.  Data represents the mean ± S.D. (n=3), where * P < 0.05, ** P < 0.001, *** P < 
0.0001 and ns = not significant. All plates had a Z- factor > 0.5. 
 
A small increase in growth inhibition was observed in transfected MDA-MB 231 cells treated 
with (a) lower concentrations of TAM (5 and 10 µM). In addition, the same was observed in 
transfected MDA-MB 231 cells treated with (b) MβCD at all concentrations. However, no 
significant difference was observed for 5-FU and AP treated transfected MDA-MB 231 cells. 
40 µM PL was used as positive control. Positive control was cut off at 50% cell death (Fig. 
4.12a), 30% (Fig. 4.12b), 60% (Fig. 4.12c) and Fig. 4.12d did not change. The positive 
control was cut off at various percentages due to the large difference between the test 
compounds and positive control.    
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Figure 4.13 shows comparative analysis of level of apoptosis, through APO% assay. The 
transfected MDA-MB 231 cells were compared to non-transfected MDA-MB 231 cells treated 
with a) TAM, b) MβCD, c) 5-FU and d) AP. 40 µM PL was used as a technical positive 
control.  Data represents the mean ± S.D. (n=3), where * P < 0.05, ** P < 0.001, *** P < 
0.0001 and ns = not significant. All plates had a Z- factor > 0.5. 
Again, a small increase in apoptosis was observed in transfected MDA-MB 231 treated with 
10 and 20 µM TAM and MβCD when compared to non-transfected cells. Interestingly, the 
efficacy of 5-FU appeared to have increased when CETP was knocked-down compared to 
non-transfected MDA-MB 231 cells. However, when transfected MDA-MB 231 cells were 
treated with AP not much difference in apoptotic activity was observed when compared to the 
non-transfected cells. In addition, there was actually a reduction in apoptotic activity in 
higher concentrations of AP in transfected cells compared to non-transfected cells.  
 
Hormone responsive BCs, such as MCF-7, are rich in cholesterol. However MDA-MB 231 
cells are triple negative cells that lack the hormone receptors as well as the HER2 receptor for 
cell growth and proliferation. In addition, it was found in our lab that the cholesterol levels in 
Figure 4.13: CETP knock-down resulted in an increase in apoptosis in transfected MDA-
MB 231 cells when treated with tamoxifen, MβCD and 5-FU when compared to non-
transfected cells 
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MDA-MB 231 cells are several times lower compared to MCF-7 cells. Previously, in (Esau et 
al., 2016), CETP knock-down was performed in BT20 cell line (another triple negative BC 
cell line) to study the role of CETP in triple negative cell line, however, it has never been 
performed in MDA-MB 231 cell line. Therefore, these results serve as baseline data for 
further investigations. From the cell viability assay, we observed a small increase in growth 
inhibition at low concentrations of TAM but not significant increase was observed at higher 
concentrations. Additionally, no significant increase in growth inhibition and cell death was 
observed in transfected MDA-MB 231 cells when treated with MβCD, 5-FU and AP. TAM, 
as discussed previously, plays an antagonistic role to estrogen therefore binds to ER to 
prevent cell proliferation and survival (Hodges et al., 2003; Mourits et al., 2001). 
Furthermore, the effects of TAM has been found to be ER dependent at low concentrations, 
while at higher concentrations the effects are independent of ER (Perry et al., 1995). This is 
evident in this study, where TAM is more effective in MCF-7 cells however, in MDA-MB 
231 cells TAM is only effective at higher concentrations (Fig. 4.12 and 4.13). 
In addition, no significant change was observed in growth inhibition and cell death in 
transfected MDA-MB 231 cells when treated with MβCD (Fig. 4.12 and 4.13). This is 
probably due to the fact that MDA-MB 231 cells are already low in cholesterol and thus the 
depletion of cholesterol does not affect the survival of MDA-MB 231 cells. No significant 
increase in growth inhibition was observed in transfected MDA-MB 231 cells when treated 
with 5-FU (Fig. 4.12). However, this was opposite to what was observed for cell death as 
there was an increase in cell death in transfected MDA-MB 231 cells. However, the results 
obtained from MTT assay may not always correlate to the results obtained from apoptosis 
assays as MTT assay measures metabolic activities and not apoptosis (Gerlier and 
Thomasset, 1986). The increase in apoptosis may indicate a possibility that CETP knock-
down resulted in a decrease in cholesterol and thus may have weakened the cell membrane. 
This could then possibly allow 5-FU to enter the cells more easily (as 5-FU targets the DNA 
replication process as mentioned previously) and thus causing an increased cell death in 
transfected MDA-MB 231 cells (Fig. 4.13). In addition, it has been found that 5-FU treated 
MDA-MB 231 cells increases Fas/FasL expression levels (Chhipa and Bhat, 2007). Fas is a 
type I transmembrane protein and it is part of the tumour necrosis factor-R (TNF-R) family 
involved in the induction of apoptosis (Huang et al., 1999). Therefore, this could possibly be 
a more effective strategy in treating ER- cancer cells. 
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AP-treated transfected MDA-MB 231 cells also did not show a significant difference in both 
growth inhibition as well as apoptosis. This was also evident in (Sagar et al., 2014) where AP 
did not induce apoptosis in BT20 cells. In addition, it was also found that AP disrupted lipid 
rafts in MCF-7 cells (35% reduction in cholesterol) however in BT20 cells, lipid rafts appear 
to be intact and could possibly suggest AP’s selectivity to ER+ BC cells (Esau et al., 2016).  
Although single treatment appears to be less effective against ER- BC cells, a combination 
treatment was performed to investigate whether TAM together with AP would increase 
growth inhibition and cell death. 
 
4.7 Analysis of growth inhibition and apoptosis in transfected and non-transfected 
MDA-MB 231 cells before and after the combination treatment of TAM and AP  
 
Fig. 4.14 illustrates growth inhibition analysis, through the MTT assay. The combination 
treatments (20 µM TAM and various concentrations of AP; 5, 10, 20 and 40 µM) were 
compared to the single treatments (TAM and AP alone at 5, 10, 20 and 40 µM) in non-
transfected MDA-MB 231 cells. Similarly, the combination treatments were compared to the 
single treatments in transfected MDA-MB 231 cells. 40 µM PL was used as a technical 
positive control. Supporting data are represented in appendix (Fig. 8.5 and 8.6). Data 
represents the mean ± S.D. (n=3), where * P < 0.05, ** P < 0.001, *** P < 0.0001 and ns = 
not significant. All plates had a Z- factor > 0.5. 
 
The results suggest that CETP knock-down does not increase the efficacy of 
chemotherapeutic drugs, hormone targeted chemotherapeutic drug or compounds. This could 
Figure 4.14: Representative of combination treatment in transfected and non-transfected 
MDA-MB 231 cells 
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possibly be due to the lower cholesterol levels in MDA-MB 231 cells however, this will be 
further investigated. Interestingly enough, combination treatment increased the efficacy of 20 
µM TAM in transfected MDA-MB 231 cells when treated along with varying concentrations 
of AP (5, 10, 20 and 40 µM)  
Subsequently, the cytotoxicity effects of various drugs and compounds were tested in HEK 
293 cell line (normal cell line). 
 
4.8 Comparison of growth inhibition in non-transfected MCF-7 cells and HEK 293 
cells after various drug treatments 
 
Fig. 4.15 represents growth inhibition, through the analysis of MTT assay, between non-
transfected MCF-7 and non-transfected HEK 293 cells treated with a) TAM (at 5, 10, 20 and 
40 µM), b) MβCD (at 5, 10, 20 and 40 µM), c) 5-FU (at 5, 10, 20 and 40 µM) and d) AP (at 
5, 10, 20 and 40 µM). 40 µM PL was used as a technical positive control. Data represents 
the mean ± S.D. (n=3), where * P < 0.05, ** P < 0.001, *** P < 0.0001 and ns = not 
significant. All plates had a Z- factor > 0.5. 
Figure 4.15: Comparison in growth inhibition between non-transfected MCF-7 and HEK 
293 cells when treated with various drugs and compounds 
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The effects of the drugs and compounds were then tested in HEK 293 cells to observe the 
cytotoxicity of each drug and compounds in normal cells. In TAM treated non-transfected 
HEK 293, we observed a much lower toxicity when compared to MCF-7 cells (Fig. 4.16a). 
This suggest that TAM is relatively non-cytotoxic even at 40 µM. It can also be observed that 
when HEK 293 cells were treated with AP (Fig. 4.16d), only higher concentrations of AP 
were quite toxic in both normal and cancer cells. However, as explained previously, we are 
targetting low concentrations that are just as effective as higher concentrations in cancer cells 
and not normal cells to reduce drug resistance. In contrast to TAM and AP, 5-FU appear to be 
cytotoxic in both normal as well as cancer cells (Fig. 4.16c). This is possibly due to the non-
specific, DNA replication inhibitory properties of 5-FU. MβCD, as discussed, is a known 
cholesterol depleter however it was observed that MβCD is more cytotoxic in normal cells 
and not effective in cancer cells at low concentrations compared to AP (Fig. 4.16b and d). 
This could imply that AP could possibly be a better cholesterol depleting agent than MβCD.  
 
5. Summary  
As mentioned previously, that this study was performed to generate baseline data for future 
experiments and therefore the key findings in this seminal study will be highlighted here. It 
was found that CETP knock-down resulted in a decrease in CE levels and thus possibly 
reducing drug resistance, as CE levels have been previously associated with the 
aggressiveness of cancers. In addition, it was also found that lower concentration of TAM (5 
µM) combined with AP and CETP knock-down enhances drug efficacy by possibly reducing 
drug resistance in ER+ BC. However, CETP knock-down still increases TAM efficacy at 
higher concentrations (20 µM) in the combination treatment in ER- BC cells. Interestingly, 5-
FU appeared to be more effective in ER- BC cells when CETP was knocked-down when 
compared to ER+ BC cells. Therefore, 5-FU in combination with AP could possibly be a 
promising strategy in treating ER- BC cells. Thus this strategy should be exploited further as 
AP has been proven, in this study as well as in one other study by (Sagar et al., 2014), that it 
is safe and low in cytotoxicity in normal cells. Nevertheless, the effects of the drugs and 
compounds in both single and combination treatments were more demarcated in MCF-7 cells 
compared to MDA-MB 231 cells. MCF-7 cells are ER+ BC cells therefore, it would be 
interesting to check the expression level of estrogen receptor gene (ESR1) in future studies. 
Prof Kaur in her previous work found that AP decreased expression of ESR1 in microarray 
experiment (unpublished result). Furthermore, the biological explanations for most of the 
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observations made during the study are not yet available at the moment as this is a totally 
new concept and background literature are limited to compare the results of this investigation. 
Future studies will be focused on understanding the effects of CETP knock-down on 
cholesterol pathway associated proteins such as; SREBP, ACAT1, LDLR, ESR1 and LXR. 
Additionally, apoptotic assays such as caspase assays, mitochondrial outer membrane 
potential assays and Western blotting on various apoptotic proteins will be performed to 
elucidate molecular mechanisms involved and thus provide a possible explanation for the 
effects we observed especially for AP treatment. Moreover, CETP knock-down should be 
performed in HEK 293 cell line for the combination treatment to observe cytotoxicity effects 
on normal cells as well as checking for CE levels. The CE levels will also be investigated in 
MDA-MB 231 (ER-) cell line after transfections. In this study, cholesterol-depleting agents in 
combination with TAM have shown to be a promising strategy in treating BC however, other 
cholesterol-depleting agents (such as cyclodextrins) along with TAM could also be 
investigated.  Subsequently, an in-vivo study will be performed to test the effect of CETP 
knock-down on tumour growth and response to various drugs or compounds. In contrast to 
knocking-down CETP, an over-expression study should be performed to observe what the 
effects would be if CETP is expressed abundantly in cancer cells and normal cells.  
6. Conclusions 
BC is amongst the top five lethal cancers in South Africa with increasing reported deaths 
yearly. Treatment for BC is limited as patients often suffer from relapses, especially from 
long term use of TAM, as it is the most common and effective treatment for BC. Therefore 
strategies in enhancing drug efficacy, while reducing drug resistance may be a beneficial 
approach. In this study, we showed that CETP knock-down increased cell death in MCF-7 
cells possibly due to a reduction in CE levels. In addition, CETP knock-down along with 
combination treatment involving a cholesterol-depleting agent such as AP increased TAM 
efficacy even at low concentrations (5 µM). Therefore, CETP could thus serve as a potential 
drug-resistance marker in cancer cells, more specifically BC. Furthermore, strategies 
targeting CEs could possibly be used as a potential combination treatment for cholesterol-
related diseases as well as reduce drug resistance and dosage  
7. Trouble-shooting 
All experiments were standardised in non-transfected MCF-7 cells and assays were 
performed in various ways for optimal results. These are as follows: 
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WESTERN BLOTTING 
Western blotting was standardised by loading various concentrations of sample lysates; 5, 10 
and 20 mg/ml. In addition, 40% and 30% bis-acrylamide solutions were tested in a gel to 
determine which pore size was more suitable. In addition, various concentrations of the 
antibodies were also tested and 2 blocking solutions (3 and 5% blocking solutions) were 
tested.  
RNA EXTRACTION  
RNA was initially extracted from the protocol using trizol (Esau et al., 2016) however, the 
purity of the RNA was poor and thus the Direct-zol™ RNA MiniPrep kit (Zymo Research, 
Inqaba, SA) was used to extract good quality RNA.  
RT-qPCPR 
RT-qPCR to quantify CETP mRNA expression was first performed using a probe-based 
assay – PrimePCR™ Assay kit (Bio-Rad, USA). However, expression levels were not able to 
be detected. This could possibly be due to the fact that probes are light sensitivity and thus 
light could have reduced probe activity during preparation of the assay. SYBR green was thus 
used as an alternative method.  
MTT ASSAY 
MTT assay was standardised with different concentrations of H2O2 (100 µM, 200 µM, 500 
µM, 1 mM, 5mM and 10 mM) and PL (5 µM, 10 µM, 20 µM and 40 µM). In addition, MTT 
solution was added in drug treated and non-treated cells and incubated at 37°C for varying 
times: 2, 3 and 4 hrs). Furthermore, different MTT solubilisation solutions (between 10% 
SDS, 10 mM HCl solution and isopropanol) were used to dissolve formazan crystals to 
determine which solubilising solution was the most effective. It was found that 40 µM PL 
gave best results with MTT incubation of 2 hrs and formazan crystals were dissolved in 10% 
SDS with 10 mM HCl solution (as isopropanol evaporated during overnight incubation).  
APO% ASSAY  
APO% was initially performed as per protocol in (Esau et al., 2016), where cells were 
detached from the plate with 15 mM and 17mM EDTA (previously found to be an effective 
chemical in lifting cells when added to media but cytotoxic if added directly to cells – the 
mechanism of this is still unknown). In addition, the same concentrations of H2O2 and PL as 
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per MTT assay were tested to pick out the optimal positive control. Furthermore, the cells 
were treated for various times (2, 3, 4, 6,  and 24 hrs) and different volumes of APO% dye 
(provided in the APO% assay kit) 0.5, 1, 1.5, 2 and 2.5 µl were tested against the cells as the 
APO% dye becomes toxic at high concentrations. However, background stain was high 
therefore, several changes to the parameters for the assay were made. Due to high 
background reading, we then followed the protocol provided by the manufacturer (APO% 
assay kit, Biocolor, UK), where media and dye were removed after incubation and cells were 
washed with 1 X PBS between each step (no EDTA step). Thereafter, APO% assay was 
performed with and without ‘dye release (provided in the APO% kit)’ and the contents of the 
wells were mixed using a plate shaker at 500rpm for 30s to 1 min. However, with the shaking 
of the plate on the plate shaker, we observed cross contamination between wells even at low 
rpm. Therefore, mixing was performed using a pipette but the absorbance values were not 
consistent between samples. Subsequently, different concentrations of trypan blue (0.4%, 
0.04%, 0.004% and 0.0004%) were added after APO% dye incubation without lifting the 
cells. This was done as trypan blue is a fluorescence quencher, thereby it was used to quench 
background noise however, it appeared that trypan blue also masked intracellular APO% dye. 
It was then decided that cells will be incubated with APO% dye without detaching the cells 
for the stipulated time, then discarded from each well and washed with 1 X PBS. Thereafter, 
cells were stored in PBS until measurement. This last method was used as it was found to 
produce the best and most consistent results.  
CHOLESTEROL ASSAY 
Cholesterol assay was standardised by a colleague in the laboratory. This was done by testing 
different volumes of various components in the assay for optimal results. These included; 
Ampliflu red (Sigma Aldrich, UK), cholesterol esterase and cholesterol oxidase. In addition, 
the assay was performed with and without catalase and it was found that with catalase, the 
background noise was reduced.  
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9. Appendix 
The following results represents the combination treatments in MCF-7 cells and MDA-MB 
231 cells with variable TAM and AP concentrations. 
 
 
 
 
  
 
Fig. 8.1 represents growth inhibition analysis, through MTT assay. The combination 
treatments were compared to the single treatments in non-transfected MCF-7 cells. The 
combination treatments were composed of a) 10 µM TAM and various AP concentrations (5, 
10, 20 and 40 µM), b) 20 µM TAM and various AP concentrations and c) 40 µM TAM and 
various AP concentrations. 40 µM PL was used as a technical positive control.  Data 
represents the mean ± standard deviation S.D. (n=3), where * P< 0.05, ** P<0.001, *** 
P<0. 0001and ns = not significant with a Z-factor > 0.5. 
Although an increase in growth inhibition was observed in the various combination 
treatments when compared to TAM single treatment, there was no significant change when 
compared to AP single treatment. Therefore, the effect observed from the combination 
treatment is more likely to be from AP.  
Figure 9.1: Representative of combination treatment on growth inhibition in non-transfected 
MCF-7 cells 
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Fig. 8.2 represents growth inhibition analysis, through MTT assay. The combination 
treatments were compared to the single treatments in transfected MCF-7 cells. The 
combination treatments were composed of a) 10 µM TAM and various AP concentrations (5, 
10, 20 and 40 µM), b) 20 µM TAM and various AP concentrations and c) 40 µM TAM and 
various AP concentrations. 40 µM PL was used as a technical positive control.  Data 
represents the mean ± standard deviation S.D. (n=3), where * P< 0.05, ** P<0.001, *** 
P<0. 0001and ns = not significant with a Z-factor > 0.5. 
 
In transfected MCF-7 cells however, we observed a significant increase in growth inhibition 
in the combination treatments compared to both single treatments especially at low 
concentrations. Therefore, the effects observed here could possibly suggest that CETP knock-
down may have increased TAM efficacy.  
 
  
Figure 9.2: Representative of combination treatment on growth inhibition in transfected 
MCF-7 cells 
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Fig. 8.3 represents apoptosis analysis, through APO% assay. The combination treatments 
were compared to the single treatments in non-transfected MCF-7 cells. The combination 
treatments were composed of a) 10 µM TAM and various AP concentrations (5, 10, 20 and 
40 µM), b) 20 µM TAM and various AP concentrations and c) 40 µM TAM and various AP 
concentrations. 40 µM PL was used as a technical positive control.  Data represents the 
mean ± standard deviation S.D. (n=3), where * P< 0.05, ** P<0.001, *** P<0. 0001and ns 
= not significant with a Z-factor > 0.5. 
Once again no significant increase in cell death was observed in the combination treatment 
compared to AP single treatment in non-transfected MCF-7 cells except at 5 µM TAM 
(which was shown in Fig. 4.10)  with various AP concentrations. However, this could 
possibly due to uneven cell number as APO% assay will be standardised further.  
 
 
 
Figure 9.3: Representative of combination treatment on cell death in non-transfected MCF-7 
cells 
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Fig. 8.4 represents apoptosis analysis, through APO% assay. The combination treatments 
were compared to the single treatments in transfected MCF-7 cells. The combination 
treatments were composed of a) 10 µM TAM and various AP concentrations (5, 10, 20 and 
40 µM), b) 20 µM TAM and various AP concentrations and c) 40 µM TAM and various AP 
concentrations. 40 µM PL was used as a technical positive control.  Data represents the 
mean ± standard deviation S.D. (n=3), where * P< 0.05, ** P<0.001, *** P<0. 0001and ns 
= not significant with a Z-factor > 0.5. 
CETP knock-down, resulted in an increased cells death in the combination treatments 
compared to both single treatments. This suggests that CETP knock-down increased TAM 
efficacy even at low concentrations.  
 
 
 
 
Figure 9.4: Representative of combination treatment on cell death in transfected MCF-7 cells 
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Fig. 8.5 represents growth inhibition analysis, through MTT assay. The combination 
treatments were compared to the single treatments in non-transfected MDA-MB 231 cells. 
The combination treatments were composed of a) 5 µM TAM and various AP concentrations 
(5, 10, 20 and 40 µM), b) 10 µM TAM and various AP concentrations and c) 40 µM TAM 
and various AP concentrations. 40 µM PL was used as a technical positive control.  Data 
represents the mean ± standard deviation S.D. (n=3), where * P< 0.05, ** P<0.001, *** 
P<0. 0001and ns = not significant with a z-factor > 0.5. 
No significant difference in growth inhibition was observed in the combination treatment 
when compared to the single treatment in non-transfected MDA-MB 231 cells (Fig. 8.5a and 
b) except at higher concentrations (Fig. 4.14b; 20 µM TAM with varying concentrations of 
AP). In addition, an enhanced activity was observed at 40 µM TAM along with AP however, 
it is a very high concentration and therefore too cytotoxic. 
 
 
 
Figure 9.5: Representative of combination treatments in non-transfected MDA-MB 231 cells 
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Fig. 8.6 represents growth inhibition analysis, through MTT assay. The combination 
treatments were compared to the single treatments in transfected MDA-MB 231 cells. The 
combination treatments were composed of a) 5 µM TAM and various AP concentrations (5, 
10, 20 and 40 µM), b) 10 µM TAM and various AP concentrations and c) 40 µM TAM and 
various AP concentrations. 40 µM PL was used as a technical positive control.  Data 
represents the mean ± standard deviation S.D. (n=3), where * P< 0.05, ** P<0.001, *** 
P<0. 0001and ns = not significant with a z-factor > 0.5. 
Similarly, in transfected MDA-MB 231 cell line, no significant increase was observed in the 
combination treatment when compared to single treatment (Fig. 8.6a, b and c). Once again, 
growth inhibition was observed at high concentrations in transfected MDA-MB 231 cell line 
(Fig. 4.14b).  
 
 
 
 
 
Figure 9.6: Representative of combination treatments in transfected MDA-MB 231 cells 
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